Pricing Log in Create free account
Saturday 17 October 2026 Export ACET’s income statement to Excel — free account

Adicet Bio, Inc.

ACET Healthcare Biotechnology

In the quarter to June 2026, EPS grew 63.4% and free cash flow grew 24.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.57 0.57 −11.09%
Market cap
$48.1M
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
4/9
Altman Z
4.96
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.60
Total sells 0.67
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — 1 — — — — — — — —
Sell — — — — — 1 — — — — — —
Insider Ownership 23.50%

Capital & Financial Ratios $m

Market Cap 48.12
Revenue 38.70
Net Income (98.97)
Free Cash Flow (84.97)
Net Debt (117.56)
Current Ratio 6.71 (at or above 1.5: strong)
Debt/Equity 0.01 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.43) (negative: loss-making)
P/S ratio 1.27
P/B ratio 0.41
Past 5Y EPS Growth —
This Y EPS Growth 62.49% (at or above 15%: strong)
Next Y EPS Growth 36.47% (at or above 15%: strong)
Next Y revenue growth (90.00%) (below 0%: weak)
Next 5Y EPS Growth 63.23% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −1.8×, against a ten-year median of −1.0×; over the ten years it ranged from −3.6× in 2020 to 29.1× in 2021.
P/S against its own 10 years 2.84%
10-year low 10-year high
P/B against its own 10 years 15.57%
10-year low 10-year high
EV/FCF against its own 10 years 44.82%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 0.09
0.07
0.01
0.01
2017 0.26
0.07
0.07
0.07
0.07
2016 0.25
0.06
0.06
0.07
0.07
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 160 176 159 118
Receivables — — — —
Inventory — — — —
Other — — — —
162 180 161 121
2023 2024 2025 Q'26
Payables 3 5 5 4
ST’ Debt — — — —
Other 13 11 — —
19 19 22 18

Compound Annual Growth %

10y 5y 3y
Sales — 6.90% 192.85%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 7.71% (18.34%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’22 25 — — — 25
’21 — 5 3 5 10
’20 2 7 3 5 18
’19 — — — 8 1
Fiscal quarters ending in the months shown.
value withheld pending a data check

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (21) (20) — — —
’25 (25) (27) (22) (21) (95)
’24 (23) (23) (22) (24) (92)
’23 (24) (25) (21) (23) (94)
’22 4 (15) (15) (19) (45)
’21 (15) (13) (10) (13) (51)
’20 (8) (12) (8) (13) (42)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (20) — — —
’25 (27) (27) (23) (21) (97)
’24 (23) (24) (22) (24) (93)
’23 (26) (26) (22) (24) (98)
’22 1 (18) (20) (25) (62)
’22 — — — — (45)
’21 (16) (15) (17) (17) (64)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (1.88) (1.99) — — —
’25 (4.96) (5.44) (4.64) (2.94) (16.95)
’24 (5.60) (5.28) (5.44) (5.12) (21.28)
’23 (11.52) (12.00) (18.56) (11.04) (52.96)
’22 1.60 (8.96) (8.48) (11.52) (27.20)
’21 (13.12) (5.44) (7.04) (7.52) (32.00)
’20 (33.18) (62.14) (45.44) (7.36) (80.16)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 816.48 105.28 96.32 100.00 120.96 17.60 12.96 7.15

Analyst estimates 2026–2028

Powerpack
High — — 2,362.86 1,339.52 347.20 284.80 349.92 152.40 60.32 17.76
People
People Employees 7 7 21 18 102 102 132 143 152 102
Revenue/emp, $m 0.00 0.00 0.39 0.06 0.18 0.10 0.19 0.00 0.00 0.00
Income, $m
Income, $m Revenue — — 8 1 18 10 25 — — —
Gross margin, % — 0.00 100.00 100.00 100.00 100.00 100.00 — — —
EBT 0 (34) (10) (28) (39) (62) (70) (143) (117) (117)
EBT margin, % 0.00 0.00 (120.87) (2,826.03) (220.59) (638.48) (279.27) 0.00 0.00 0.00
Net income 0 (34) (9) (28) (37) (62) (70) (143) (117) (117)
Depreciation 0 0 1 1 1 2 3 26 5 2
Per share, $
Per share, $ Revenue 0.00 0.00 67.22 7.44 39.13 5.03 9.73 0.00 0.00 0.00
Earnings 0.00 (942.76) (76.42) (210.48) (80.16) (32.00) (27.20) (52.96) (21.28) (16.95)
Cash flow 0.00 (306.84) (149.38) (208.54) (90.82) (26.39) (17.44) (34.84) (16.82) (13.82)
Capex 0.00 (1.23) (7.20) (7.12) (2.16) (6.74) (6.54) (1.66) (0.20) (0.25)
Free cash flow 0.00 (308.07) (156.58) (215.66) (92.99) (33.13) (23.97) (36.50) (17.02) (14.07)
Book value 0.00 (891.87) 856.24 (451.50) 240.06 156.70 113.86 63.26 33.98 23.10
Shares, m 4 0 0 0 0 2 3 3 5 7
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 — — —
P/S — — 0.00 0.00 5.74 55.64 9.10 — — —
P/B — — 1.13 0.00 0.94 1.79 1.20 — — —
EV/Sales — — 0.00 0.00 1.60 29.10 2.92 — — —
EV/FCF — — (0.50) 1.39 (0.67) (4.42) (1.83) — — —
Cash, $m
Cash, $m Operating cash flow 0 (11) (18) (28) (42) (51) (45) (94) (92) (95)
Capex 0 0 (1) (1) (1) (13) (17) (4) (1) (2)
Free cash flow 0 (11) (19) (29) (43) (64) (62) (98) (93) (97)
Balance, $m
Balance, $m Working capital — 50 104 49 78 266 241 143 161 139
Total debt — — — 114 20 19 19 — — 1
Net debt — (53) (108) (62) (95) (278) (258) (160) (176) (158)
Shareholders’ equity — (32) 104 (60) 110 303 292 170 187 159
Returns, %
Returns, % ROA 0.00 (122.40) (11.26) (29.38) (31.16) (25.16) (20.84) (53.03) (54.79) (56.62)
ROIC — 0.00 0.00 0.00 (161.01) (150.07) (130.74) (908.10) (773.91) (5,773.17)
ROE 0.00 105.79 (25.73) (128.37) (148.31) (30.03) (23.44) (61.69) (65.65) (67.55)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Mar 2022

Charts ten years each

Adicet Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CRBU Caribou Biosciences, Inc. $49.8M — (loss-making) — (loss-making) −43.79% (below 0%: shrinking) n/m −33.16% (below 0%: shrinking) 100.00% (1,690.39%) Compare
MREO Mereo BioPharma Group plc - Sponsored ADR $49.3M — (loss-making) — (loss-making) — n/m +21.02% (above 0%: growing) 0.00% 0.00% Compare
HYPD Hyperion DeFi, Inc. $49.0M — (loss-making) 3.6× +2,333.33% (above 0%: growing) n/m +86.82% (above 0%: growing) 100.00% 8,668.63% Compare
HOWL Werewolf Therapeutics, Inc. $48.5M — (loss-making) — (loss-making) +256.11% (above 0%: growing) n/m +146.46% (above 0%: growing) 100.00% 34.09% Compare
ELTX Elicio Therapeutics, Inc. $48.2M — (loss-making) — (loss-making) −55.27% (below 0%: shrinking) n/m +8.77% (above 0%: growing) 0.00% 0.00% Compare
ACET Adicet Bio, Inc. $48.1M — (loss-making) — (loss-making) +727.73% (above 0%: growing) n/m +24.94% (above 0%: growing) 0.00% 0.00%
KLRS Kalaris Therapeutics Inc. $47.8M — (loss-making) — — n/m +11.91% (above 0%: growing) 0.00% 0.00% Compare
IBIO iBio, Inc. $47.6M — (loss-making) — (loss-making) +100.00% (above 0%: growing) n/m −35.33% (below 0%: shrinking) 100.00% 0.00% Compare
CLNN Clene Inc. $47.0M — (loss-making) — (loss-making) +233.33% (above 0%: growing) n/m +45.43% (above 0%: growing) 60.00% (5,941.11%) Compare
Median of peers $48.3M — — +166.67% — +16.47% 80.00% 0.00%

All 614 Biotechnology stocks →

Adicet Bio, Inc. (ACET) key facts

  • Adicet Bio, Inc. (ACET) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ACET traded at $4.57, a market capitalization of $48.1 million.
  • Return on equity was −67.6% and debt-to-equity 0.01.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 4.96 (safe zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.

Adicet Bio, Inc. (ACET) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ACET · Data as of Mar 31, 2022 · For information only; not investment advice. · © 2026 stockrow.com